Prospective Outcomes Study: Vectra® DA Guided Care Compared to Usual Care



Status:Recruiting
Conditions:Arthritis, Rheumatoid Arthritis
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:18 - 80
Updated:8/1/2018
Start Date:June 2016
End Date:August 2022
Contact:David Chernoff, MD
Email:dchernoff@crescendobio.com
Phone:650-351-3056

Use our guide to learn which trials are right for you!

In this 12-month multi-center prospective, site-randomized, two-arm trial, approximately 318
biologic-naïve subjects with RA who are candidates for treatment intensification due to
inadequate response to MTX monotherapy will be enrolled at up to 60 study sites.

To determine whether a strategy of Vectra DA guided care (Arm A), compared with usual care
(Arm B), achieves non-inferior clinical outcomes while reducing the cost of treatment in
patients with active RA and an inadequate response to MTX monotherapy.

Inclusion Criteria:

Subjects will be eligible to participate in the study if they meet all the following
criteria:

1. Willing and able to sign an ICF

2. Age 18 to 80 years at enrollment

3. Meets the 2010 ACR/EULAR criteria and/or 1987 criteria for RA, as determined by a
board-certified rheumatologist ≥3 months prior to enrollment

4. Received uninterrupted treatment with weekly MTX begun ≥3 months prior to enrollment,
at a stable dose of ≥15 mg per week for at least 4 weeks prior to enrollment. A
history of therapy with split dose oral MTX or parenteral MTX is acceptable only if
the weekly MTX dose was always ≤20 mg/week during the 3 months prior to enrollment.

5. CDAI >10 as assessed by the Investigator at screening

6. At least 3 swollen joints (SJC ≥3) and 3 tender joints (TJC ≥3) out of 28 joints as
assessed by the Investigator at screening

7. Must be eligible for treatment intensification with non-biologic and biologic DMARDs

8. Documented evidence of seropositivity (RF and/or anti-CCP antibodies). Seronegative
subjects are allowed if erosive disease attributable to RA is documented on X-rays.

Exclusion Criteria:

Subjects will be ineligible to participate in the study if they meet any of the following
criteria:

1. Use of a non-biologic DMARD other than MTX within 3 months prior to enrollment

2. MTX administered SQ or as an oral split dose at >20 mg/week any time during the 3
months prior to enrollment

3. Two or more DMARDs used in combination (i.e., concomitantly), including but not
limited to: MTX, HCQ, SSZ, LEF, cyclosporine, azathioprine, gold or penicillamine any
time prior to enrollment

4. Biologic DMARD or JAKi use any time prior to enrollment

5. Any contraindication to use of MTX, HCQ, LEF or biologic DMARDs

6. Opiate use during the 2 weeks prior to enrollment

7. Oral corticosteroids during the month prior to enrollment at a dosage >10 mg/day
prednisone (or equivalent) or at a non-stable dose ≤10 mg/day prednisone (or
equivalent)

8. MTX intolerance prior to enrollment that limits its use

9. Inflammatory joint disease (other than RA) or any other systemic autoimmune disorder.
(Osteoarthritis is not a basis for exclusion.)

10. Primary or secondary immunodeficiency

11. Active infection (excluding fungal infection of nail beds); or acute or chronic
infection requiring hospitalization or treatment with parenteral systemic antibiotics
within one month of enrollment or treatment with oral antibiotics within 2 weeks of
enrollment

12. IA, intravenous or IM corticosteroids during the month prior to enrollment

13. Initiation or non-stable dosing of NSAIDs within 2 weeks prior to enrollment

14. Vectra DA testing within 3 months prior to enrollment

15. Live vaccine within 90 days of enrollment

16. Active substance abuse or psychiatric illness likely to interfere with protocol
conduct

17. History of severe allergic or anaphylactic reaction to any monoclonal antibody therapy

18. Known infection with HIV (HIV testing will not be a requirement for trial entry); a
past or current history of hepatitis B virus or hepatitis C virus infection

19. History of malignancy within the past five years or any evidence of persistent
malignancy, except fully excised basal cell or squamous cell carcinomas of the skin,
or cervical carcinoma in situ that has been treated or excised in a curative procedure

20. Pregnancy or inadequate contraception in women of childbearing potential

21. Breast feeding or lactating

22. Medical, psychiatric, cognitive or other conditions that, in the opinion of the
Investigator, may compromise the ability of the subject to understand the study
information, to give informed consent, to comply with the trial protocol, or to
complete the study

23. Presently enrolled in another clinical trial

24. Vectra DA score at screening that is outside the applicable range as required for
subject enrollment

Note: Screening for TB is not required for subjects participating in the study. If an
Investigator is considering a subject for treatment with a biologic DMARD in the study,
guidelines for TB screening need to be followed.
We found this trial at
40
sites
Clearwater, Florida 33765
Principal Investigator: Robert Levin, MD
Phone: 727-734-6631
?
mi
from
Clearwater, FL
Click here to add this to my saved trials
500 S State St
Ann Arbor, Michigan 48109
(734) 764-1817
Principal Investigator: Elena Schiopu, MD
Phone: 734-647-8173
University of Michigan The University of Michigan was founded in 1817 as one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Arlington, Virginia 22205
Principal Investigator: Phillip Kempf, MD
Phone: 703-525-3069
?
mi
from
Arlington, VA
Click here to add this to my saved trials
Baltimore, Maryland 21286
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Berkeley Heights, New Jersey 07922
Principal Investigator: Lauren Kennish, MD
Phone: 908-277-8747
?
mi
from
Berkeley Heights, NJ
Click here to add this to my saved trials
1909 214th Street Southeast
Bothell, Washington 98021
Principal Investigator: Jeff Peterson, MD
Phone: 425-248-2635
?
mi
from
Bothell, WA
Click here to add this to my saved trials
Bowling Green, Kentucky 42101
Principal Investigator: Asad Fraser, MD
Phone: 270-393-2786
?
mi
from
Bowling Green, KY
Click here to add this to my saved trials
Burke, Virginia 22015
Principal Investigator: Neil Stahl, MD
Phone: 703-425-4435
?
mi
from
Burke, VA
Click here to add this to my saved trials
Chula Vista, California 91910
Principal Investigator: Dana Reddy, MD
Phone: 619-427-1721
?
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Covina, California 91723
Principal Investigator: Samy Metyas, MD
Phone: 626-869-5730
?
mi
from
Covina, CA
Click here to add this to my saved trials
24 Hospital Avenue
Danbury, Connecticut 06810
Principal Investigator: Michael Spiegel, MD
Phone: 203-794-5610
?
mi
from
Danbury, CT
Click here to add this to my saved trials
1125 Old Route 220 North
Duncansville, Pennsylvania 16635
Principal Investigator: Alan Kivitz, MD
Phone: 814-693-0300
?
mi
from
Duncansville, PA
Click here to add this to my saved trials
Huntsville, Alabama 35801
Principal Investigator: William J Shergy, MD
Phone: 256-704-7098
?
mi
from
Huntsville, AL
Click here to add this to my saved trials
Lansing, Michigan 48910
Principal Investigator: Joshua June, DO
Phone: 517-272-9727
?
mi
from
Lansing, MI
Click here to add this to my saved trials
Lansing, Michigan 48917
Principal Investigator: Patricia Cagnoli, MD
Phone: 517-886-5466
?
mi
from
Lansing, MI
Click here to add this to my saved trials
Las Vegas, Nevada 89128
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Lewes, Delaware 19958
Principal Investigator: Jose Pando, MD
Phone: 302-644-2633
?
mi
from
Lewes, DE
Click here to add this to my saved trials
Memphis, Tennessee 38104
Principal Investigator: Syed Hasan Raza, MD
Phone: 901-516-2212
?
mi
from
Memphis, TN
Click here to add this to my saved trials
Mesquite, Texas 75150
Principal Investigator: Atul Singhal, MD
Phone: 972-288-2600
?
mi
from
Mesquite, TX
Click here to add this to my saved trials
Middleburg Heights, Ohio 44130
Principal Investigator: Isam Diab, MD
Phone: 440-826-0742
?
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
Midland Park, New Jersey 07432
Principal Investigator: Evan Leibowitz, MD
Phone: 201-444-4530
?
mi
from
Midland Park, NJ
Click here to add this to my saved trials
Myrtle Beach, South Carolina 29572
Principal Investigator: Douglas Conaway, MD
Phone: 843-497-5929
?
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
Nassau Bay, Texas 77058
Principal Investigator: Prashanth Sunkureddi, MD
Phone: 281-240-1045
?
mi
from
Nassau Bay, TX
Click here to add this to my saved trials
Onalaska, Wisconsin 54650
Principal Investigator: Carol Danning, MD
Phone: 608-775-7008
?
mi
from
Onalaska, WI
Click here to add this to my saved trials
Palm Harbor, Florida 34684
Principal Investigator: Anthony Sebba, MD
Phone: 727-210-2555
?
mi
from
Palm Harbor, FL
Click here to add this to my saved trials
29200 Harper Avenue
Saint Clair Shores, Michigan 48081
Principal Investigator: Amar Majjihoo, MD
Phone: 586-777-7577
?
mi
from
Saint Clair Shores, MI
Click here to add this to my saved trials
Salisbury, North Carolina 28144
Principal Investigator: Rakesh Patel, MD
?
mi
from
Salisbury, NC
Click here to add this to my saved trials
1340 Wonder World Drive
San Marcos, Texas 78666
Principal Investigator: Alissa Hassan, MD
Phone: 608-848-8900
?
mi
from
San Marcos, TX
Click here to add this to my saved trials
Seattle, Washington 98122
Principal Investigator: Anthony Krajcer, MD
Phone: 206-860-5433
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Smithtown, New York 11787
Principal Investigator: Peter Rumore, MD
Phone: 631-360-7778
?
mi
from
Smithtown, NY
Click here to add this to my saved trials
Spokane, Washington 99204
Principal Investigator: Howard Kenney, MD
Phone: 509-462-2808
?
mi
from
Spokane, WA
Click here to add this to my saved trials
Statesville, North Carolina 28625
Principal Investigator: Bob Wodecki, MD
Phone: 704-872-8711
?
mi
from
Statesville, NC
Click here to add this to my saved trials
Summit, New Jersey 07901
Principal Investigator: Elliott Rosenstein, MD
Phone: 908-522-6156
?
mi
from
Summit, NJ
Click here to add this to my saved trials
Tavares, Florida 32778
Principal Investigator: Kenneth Stark, MD
Phone: 352-343-7735
?
mi
from
Tavares, FL
Click here to add this to my saved trials
Tupelo, Mississippi 38801
Principal Investigator: Charles King, MD
Phone: 662-377-5131
?
mi
from
Tupelo, MS
Click here to add this to my saved trials
Washington, District of Columbia 20060
Principal Investigator: Mercedes Quinones, MD
Phone: 202-865-3326
?
mi
from
Washington,
Click here to add this to my saved trials
Wheaton, Maryland 20902
Principal Investigator: Paul DeMarco, MD
Phone: 301-942-7833
?
mi
from
Wheaton, MD
Click here to add this to my saved trials
Wheelersburg, Ohio 45694
Principal Investigator: Rajesh Kataria, MD
Phone: 740-355-8562
?
mi
from
Wheelersburg, OH
Click here to add this to my saved trials
1907 Tradd Ct
Wilmington, North Carolina 28401
(910) 799-5500
Principal Investigator: Ronald George, MD
Phone: 910-815-6108
PMG Research of Wilmington PMG Research of Wilmington has two offices situated in a 1...
?
mi
from
Wilmington, NC
Click here to add this to my saved trials
Wyomissing, Pennsylvania 19610
Principal Investigator: Robert Griffin, MD
Phone: 610-375-2466
?
mi
from
Wyomissing, PA
Click here to add this to my saved trials